Thanks, Guts. I believe we are two or three quarters away from launching in the US, but this is nice to see. Btw, I noticed a small mistake in the "Product Characteristics" section of the bottom table. Specifically, "bubble gum" is depicted as the flavor instead of "wild cherry". I have no idea if that matters, but you may want to bring this to the company's attention just in case. I also read "OTC monograph not final". So there appears to be some more work to do here, in addition to the $1.5M to $2M required for the US launch. Nonetheless, though I'm not focused on RapiMeds, it will be a very big deal if Scrips can succeed with RapiMeds in the US.